New chemo combo may offer hope for rare, aggressive gut cancer

NCT ID NCT04325425

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a chemotherapy regimen called mFOLFIRINOX works better than the standard platinum-etoposide combination for people with a rare, fast-growing type of neuroendocrine cancer that has spread. About 218 adults with this cancer will be randomly assigned to one of the two treatments. The goal is to see which regimen delays cancer growth longer and to find genetic markers that predict which treatment is best for each person.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE; CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE; CARCINOMA

Contacts and locations

Locations

CH de Troyes
RECRUITING

Troyes, 10003, France
Centre Hospitalier de Saint Malo
RECRUITING

St-Malo, 35403, France
Chu Dijon Bourgogne
RECRUITING

Dijon, 21000, France
Chu de Caen
RECRUITING

Caen, 14033, France
Chu de Limoges - Dupuytren
RECRUITING

Limoges, 87042, France
Institut de Cancérologie de Bourgogne
RECRUITING

Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.